Novo Nordisk shares slip after rebrand to Novo draws analyst caution
Analysts responded cautiously to the Danish drugmaker's corporate name change, pressuring the stock.
TR
By Tom Reyes · Markets Editor
Sep 16 05:03 ETSource: ad-hoc-news.de
The wire
- 01Novo Nordisk stock fell following its rebrand to 'Novo' and a cautious analyst reception.
- 02The reaction signals investor skepticism about the company's strategic reset amid obesity market competition.
- 03Whether the rebrand accompanies broader pipeline or cost changes remains to be seen.
From the source
Read at news.google.comNovo Nordisk stock falls as rebrand to Novo meets cautious analyst response